Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETON NASDAQ:IOBT NASDAQ:ITOS NASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETONEton Pharmaceuticals$14.49-6.9%$16.40$3.25▼$21.48$417.28M1.18266,913 shs442,978 shsIOBTIO Biotech$1.47+5.0%$1.30$0.66▼$1.73$92.23M0.36287,012 shs460,293 shsITOSiTeos Therapeutics$10.29+0.8%$9.27$4.80▼$18.13$390.77M1.49695,746 shs859,526 shsSLDBSolid Biosciences$5.26-3.0%$4.00$2.41▼$10.37$420.13M2.341.21 million shs610,739 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETONEton Pharmaceuticals-1.33%+7.13%-0.95%+24.98%+364.48%IOBTIO Biotech-2.78%-6.98%-5.41%+63.36%+12.90%ITOSiTeos Therapeutics-0.20%+0.39%+1.79%+80.71%-33.05%SLDBSolid Biosciences-1.81%+8.92%+12.22%+100.74%-22.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationETONEton Pharmaceuticals2.7297 of 5 stars3.53.00.00.02.01.70.6IOBTIO Biotech3.2474 of 5 stars3.73.00.00.02.52.50.6ITOSiTeos Therapeutics3.3744 of 5 stars4.12.00.00.02.03.30.6SLDBSolid Biosciences3.4736 of 5 stars4.62.00.00.02.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETONEton Pharmaceuticals 3.00Buy$29.67104.74% UpsideIOBTIO Biotech 3.33Buy$9.33534.92% UpsideITOSiTeos Therapeutics 2.14Hold$15.8654.10% UpsideSLDBSolid Biosciences 3.17Buy$15.10187.07% UpsideCurrent Analyst Ratings BreakdownLatest IOBT, SLDB, ITOS, and ETON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/17/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/6/2025SLDBSolid BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.005/29/2025ETONEton PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $35.005/28/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$13.00 ➝ $12.005/28/2025ITOSiTeos TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$10.00 ➝ $12.005/22/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$16.005/19/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/16/2025ETONEton PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $26.005/16/2025SLDBSolid BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $17.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETONEton Pharmaceuticals$39.01M9.96N/AN/A$0.94 per share15.41IOBTIO BiotechN/AN/AN/AN/A$0.71 per shareN/AITOSiTeos Therapeutics$35M11.25N/AN/A$16.16 per share0.64SLDBSolid Biosciences$8.09M50.40N/AN/A$3.43 per share1.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETONEton Pharmaceuticals-$3.82M-$0.18N/A28.98N/A-9.49%-3.15%-1.08%8/4/2025 (Estimated)IOBTIO Biotech-$95.49M-$1.49N/AN/AN/AN/A-162.55%-125.08%8/12/2025 (Estimated)ITOSiTeos Therapeutics-$134.41M-$3.04N/AN/AN/AN/A-21.37%-18.55%8/6/2025 (Estimated)SLDBSolid Biosciences-$124.70M-$2.99N/AN/AN/AN/A-68.15%-55.33%8/12/2025 (Estimated)Latest IOBT, SLDB, ITOS, and ETON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025SLDBSolid Biosciences-$0.53-$0.59-$0.06-$0.59N/AN/A5/13/2025Q1 2025ETONEton Pharmaceuticals$0.09$0.07-$0.02-$0.06$14.33 million$17.28 million4/28/2025Q1 2025ITOSiTeos Therapeutics-$0.94-$0.80+$0.14-$0.80$9.35 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETONEton PharmaceuticalsN/AN/AN/AN/AN/AIOBTIO BiotechN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETONEton Pharmaceuticals1.231.971.43IOBTIO BiotechN/A2.322.32ITOSiTeos TherapeuticsN/A14.1314.13SLDBSolid BiosciencesN/A10.8910.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETONEton Pharmaceuticals27.86%IOBTIO Biotech54.76%ITOSiTeos Therapeutics97.16%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipETONEton Pharmaceuticals16.03%IOBTIO Biotech4.80%ITOSiTeos Therapeutics12.50%SLDBSolid Biosciences1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETONEton Pharmaceuticals2026.82 million22.52 millionOptionableIOBTIO Biotech3065.88 million62.72 millionNot OptionableITOSiTeos Therapeutics9038.27 million33.49 millionOptionableSLDBSolid Biosciences10077.51 million76.04 millionOptionableIOBT, SLDB, ITOS, and ETON HeadlinesRecent News About These CompaniesSHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the FirmJuly 10 at 8:00 AM | prnewswire.comSLDB Solid Biosciences Inc. - Seeking AlphaJuly 10 at 4:43 AM | seekingalpha.comSolid Biosciences receives FDA approval for CPVT gene therapy INDJuly 10 at 4:43 AM | investing.comSolid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular ... - Yahoo FinanceJuly 10 at 4:43 AM | finance.yahoo.comCiti Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PTJuly 10 at 4:43 AM | msn.comSolid Biosciences Stock Pops On US, Canada Nod For Gene Therapy Trials: Retail Buzz SpikesJuly 9 at 2:59 AM | msn.comSLDB - Solid Biosciences Inc Price vs Fair Value - MorningstarJuly 8 at 9:54 PM | morningstar.comMSolid Biosciences Inc. (SLDB) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comSLDB - Solid Biosciences Inc Valuation - MorningstarJune 27, 2025 | morningstar.comMSolid Biosciences (NASDAQ:SLDB) Raised to "Strong-Buy" at CitigroupJune 27, 2025 | marketbeat.comSolid Biosciences Inc. (SLDB) Cash Flow - Yahoo FinanceJune 26, 2025 | finance.yahoo.comCitigroup Initiates Coverage of Solid Biosciences (SLDB) with Buy RecommendationJune 26, 2025 | msn.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Buy" by BrokeragesJune 21, 2025 | marketbeat.comSarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences...June 18, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Receives Buy Rating from HC WainwrightJune 17, 2025 | marketbeat.comSolid Biosciences Approves Equity Plan Amendment at MeetingJune 13, 2025 | tipranks.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2025 | globenewswire.comSolid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthroughMay 28, 2025 | investing.comSolid Biosciences to Participate at the Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comTruist maintains buy on Solid Biosciences stock, price target at $16May 18, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeSarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesBy Leo Miller | June 18, 2025View Sarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesChipotle: Too Spicy for Smart Money to Resist After Stock SplitBy Jeffrey Neal Johnson | July 11, 2025View Chipotle: Too Spicy for Smart Money to Resist After Stock SplitIOBT, SLDB, ITOS, and ETON Company DescriptionsEton Pharmaceuticals NASDAQ:ETON$14.49 -1.07 (-6.88%) Closing price 04:00 PM EasternExtended Trading$14.49 0.00 (0.00%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.IO Biotech NASDAQ:IOBT$1.47 +0.07 (+5.00%) Closing price 04:00 PM EasternExtended Trading$1.42 -0.04 (-3.06%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.iTeos Therapeutics NASDAQ:ITOS$10.29 +0.08 (+0.78%) Closing price 04:00 PM EasternExtended Trading$10.33 +0.04 (+0.35%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.Solid Biosciences NASDAQ:SLDB$5.26 -0.16 (-2.95%) Closing price 04:00 PM EasternExtended Trading$5.27 +0.01 (+0.21%) As of 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
